Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab

NCT03107793 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn Disease

Interventions

DRUG: Ustekinumab

Sponsor

Janssen-Cilag Ltd.